A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS-CN-INS
- Sponsors Eli Lilly and Company
Most Recent Events
- 25 Jul 2024 Status changed from active, no longer recruiting to completed.
- 18 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2023 Planned End Date changed from 30 Aug 2024 to 1 Jul 2024.